ARCHIVES

SWOG Opens Phase II Trial Of CuraGen’s HDAC Inhibitor For B-Cell Lymphoma

This article is from The Cancer Letter archive.

Vol. 29 No. 9 | September 29, 2006

Download PDF Visit The Full Archive

Related Articles

New System Devised To Help Identify Emerging Comprehensive Centers

October 10, 1975

FDA Committee Can’t Find “Reasonable” Evidence Alkylating Agent Clinical Use Is Carcinogenic

September 10, 1976

FDA Adopts Plan For Drug Approval After Phase 2; Chabner Unconvinced

November 4, 1988

New research Suggested For Immunobiology

November 18, 1977

Eight States Get Cervical Cancer Screening Planning Contracts

June 21, 1974

Two More Treatment Programs Moved To DCT; Rauscher Ponders Fate of Cooperative Groups

April 18, 1975